Close
Solutions
Online Inquiry
Global Services

Smarter™ Marked CAR Construction Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

CAR-engineered T cell therapy has been rapidly developing in recent years. It has achieved impressive curative effects on many types of cancers. However, there are some adverse events following treatment with CAR-T cell therapy. Marked CAR-T cells express not only CARs but also tumor epitopes that can be recognized by an existing monoclonal antibody. If severe adverse effects take place, administration of the specific monoclonal antibody can clear CAR-T cells with no additional off-tumor effects. These monoclonal antibodies are simultaneously able to treat tumors as well. Creative Biolabs provides design and construction services for Marked CAR.

arked chimeric antigen receptor models and concepts

Marked chimeric antigen receptor models and concepts
Nature Reviews Cancer. 2016.

In an animal test, CAR-T cells that express truncated human EGFR polypeptide and retain the intact binding epitope of pharmaceutical-grade anti-EGFR monoclonal antibody (cetuximab), exhibited susceptibility to elimination by cetuximab. The human EGFR polypeptide provides a cell surface marker for in vitro tracking of CAR-T cells through both flow cytometry and immunohistochemistry, and a target for cetuximab mediated antibody-dependent cellular cytotoxicity and in vivo elimination. Another example is that marked CAR-T cells expressing a 136-amino-acid protein that can be recognized by anti-CD34 and anti-CD20 antibodies. This design allows selection with the anti-CD34 monoclonal antibody and it also makes CAR-T cells highly susceptible to lysis by the therapeutic monoclonal rituximab.

With consistent dedications in research and testing, Creative Biolabs has developed many novel CAR constructions that allow the clear of CAR-T cells in time and thus limit the side effects. The great advantage of marked CAR is that it can clear CAR-T cells and alleviate adverse symptoms through administration of a monoclonal antibody.

References

  1. Fesnak, et al. "Engineered T cells: the promise and challenges of cancer immunotherapy." Nature Reviews Cancer 16.9 (2016): 566-581.
  2. Philip, et al. "A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy." Blood 124.8 (2014): 1277-1287.
  3. Wang, et al. "A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells." Blood 118.5 (2011): 1255-1263.
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.